Tema ETF Trust Tema Obesity & Cardiometabolic ETF
HRTS

$34.68

1.87%

Market Cap: $88.4M

0

Funds holding %

of 6,728 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

29% more funds holding

Funds holding: 14 [Q1] → 18 (+4) [Q2]

25% more capital invested

Capital invested by funds: $16.7M [Q1] → $20.9M (+$4.18M) [Q2]

0.61% less ownership

Funds ownership: 28.56% [Q1] → 27.94% (-0.61%) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for HRTS.

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Tap the Weight-Loss Drug Market With These ETFs

Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.

Tap the Weight-Loss Drug Market With These ETFs

Disruptive Theme of the Week: Playing Defense

When markets correct, it is a good time to revisit which equity market sectors are “defensive” themes. Certain products and services are nondiscretionary in nature that we cannot live without.

Disruptive Theme of the Week: Playing Defense

How to capitalize on the weight loss revolution with Tema Obesity & Cardiometabolic ETF (HRTS)

The weight loss revolution sparked by Novo Nordisk last year is attracting many investors towards the high risk biotech sector. An ETF like HRTS gives a lower risk exposure to the sector.

How to capitalize on the weight loss revolution with Tema Obesity & Cardiometabolic ETF (HRTS)

HRTS: Generating Alpha In Obesity Treatment

The Tema Obesity & Cardiometabolic ETF is a new actively managed fund focusing on the obesity treatment market. The investment strategy includes a mix of cash flow-positive companies, high-growth companies, and start-ups with promising technology. An interview with the PM increased my understanding and confidence in the portfolio construction and strategy.

HRTS: Generating Alpha In Obesity Treatment

Zacks Investment Research

ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment

Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug candidate.

ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment

HRTS: Exposure To GLP-1 Drug Developers Means Plenty Of Upside

By 2030, the weight loss drug market is estimated to reach a significant size, attracting many competitors due to the high prevalence of obesity-related comorbidities. The Tema Obesity & Cardiometabolic ETF offers exposure to leading biotech and pharma companies in the anti-obesity drugs market, focusing on GLP-1 medicines. HRTS outperformed the market since its inception, with a focus on mid-cap pharma businesses and a moderate risk profile, making it a favorable investment in the expanding cardiometabolic drugs market.

HRTS: Exposure To GLP-1 Drug Developers Means Plenty Of Upside

Bloomberg Markets and Finance

Looking at Next Gen of Weight Loss: Tema ETFs CEO

Tema Obesity & Cardiometabolic ETF (HRTS) currently holds 46 companies focused on GLP-1, obesity, and weight-loss. Tema ETFs CEO and Founder Maurits Pot says we're trying to build a product that goes beyond GLP-1 and around for decades, so being an early investor is really important.

Looking at Next Gen of Weight Loss: Tema ETFs CEO

Zacks Investment Research

Play These New ETFs to Tap Lucrative Weight Loss Drug Market

Global obesity rates have nearly tripled since 1975, per WHO and Goldman Sachs. The growing usage of GLP-1 drugs in weight management now makes the industry a thriving one.

Play These New ETFs to Tap Lucrative Weight Loss Drug Market

Fighting Obesity Using ETFs

Weight loss has long been a challenge for many people, me included. Indeed, there are an estimated 1 billion individuals living with obesity, and the Obesity World Atlas estimates this could rise to 1.9 billion by 2035.

Fighting Obesity Using ETFs

Thematic ETF Winners of the Q1 2024 Earnings Season

Digging into the first quarter's earnings season allows us to uncover the winning themes of the period as captured by ETFs.

Thematic ETF Winners of the Q1 2024 Earnings Season

See News Rankings